 |
 |

Association Between Development of Hypothyroidism and Improved Survival in Patients With Head and Neck Cancer
Marc Nelson, MD;
Aleck Hercbergs, MD;
Lisa Rybicki, MS;
Marshall Strome, MD
Arch Otolaryngol Head Neck Surg. 2006;132:1041-1046.
Objective To determine if the development of hypothyroidism has an effect on the outcome of advanced-stage head and neck squamous cell carcinoma.
Design Retrospective database analysis.
Setting Tertiary care center.
Patients The study population comprised 155 patients with advanced-stage head and neck squamous cell carcinoma.
Interventions Patients underwent radiation therapy alone or in combination with chemotherapy and surgery when indicated.
Main Outcome Measures Kaplan-Meier analysis was used to assess survival, not adjusting for timing of the detection of hypothyroidism. The following 2 analyses were then performed to adjust for the timing of detection: (1) hypothyroidism was assessed as a time-varying covariate in a Cox proportional hazards model and (2) a landmark analysis was conducted at 9, 12, 15, 18, 21, and 24 months using the Kaplan-Meier method.
Results Of the 155 patients, 59 developed hypothyroidism, defined as a thyrotropin level greater than 5.5 mIU/L (institutional value). An unadjusted Kaplan-Meier analysis indicated that patients who develop hypothyroidism have significantly better survival than patients who do not (P<.001, log-rank test). After adjusting for the timing of hypothyroidism, a Cox proportional hazards analysis indicated that survival was better, but not statistically significant, for patients who developed hypothyroidism (hazard ratio, 0.62; P = .12); results from a landmark analysis supported this finding (P values ranged from .11 to .19).
Conclusions Development of hypothyroidism may be associated with improved survival and increased recurrence-free survival. Larger, prospective studies appear warranted to test the beneficial effect of hypothyroidism.
Author Affiliations: Head and Neck Institute (Drs Nelson and Strome), and Departments of Radiation Oncology (Dr Hercbergs) and Biostatistics (Ms Rybicki), Cleveland Clinic Foundation, Cleveland, Ohio.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor
Davis et al.
Am. J. Physiol. Endocrinol. Metab. 2009;297:E1238-E1246.
ABSTRACT
| FULL TEXT
Thyroid Function and Cancer Risk: A Prospective Population Study
Hellevik et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:570-574.
ABSTRACT
| FULL TEXT
Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
Garfield et al.
JCO 2008;26:5131-5132.
FULL TEXT
The Association of Thyroid Dysfunction with All-Cause and Circulatory Mortality: Is There a Causal Relationship?
Volzke et al.
J. Clin. Endocrinol. Metab. 2007;92:2421-2429.
ABSTRACT
| FULL TEXT
Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Garfield et al.
JNCI J Natl Cancer Inst 2007;99:975-976.
FULL TEXT
Hypothyroidism in the Patient With Cancer: How Much Thyroid Supplementation Is "Safe"?
Hercbergs and Davis
Arch Otolaryngol Head Neck Surg 2007;133:625-626.
FULL TEXT
|